Matrix Metallopropteinases in Heart Failure

Author(s): Dimitris Tousoulis, Anna-Maria Kampoli, Nikolaos Papageorgiou, Charalambos Antoniades, Gerasimos Siasos, George Latsios, Eleftherios Tsiamis, Christodoulos Stefanadis.

Journal Name: Current Topics in Medicinal Chemistry

Volume 12 , Issue 10 , 2012

Become EABM
Become Reviewer

Abstract:

Heart failure (HF) represents a complex multifactorial syndrome, characterized by crucial structural and functional abnormalities of the myocardium. Matrix metalloproteinases are associated with left ventricular dysfunction, adverse left ventricular remodelling and prognosis after acute myocardial infarction. There is a strong association between oxidative stress and MMPs in the pathophysiology of HF. As MMPs are strongly associated to the pathogenesis and pathophysiology of HF, several agents have been proposed as potential modulators of these molecules. Classical agents such as statins, angiotensin converting enzyme inhibitors (ACEIS) and beta-blockers and a variety of novel agents have been implicated in the pathogenesis and progression of heart failure via the matrix metalloproteinases pathway and consist of possible future therapeutic targets.

Keywords: Clinical implications, dysfunction, heart failure, left ventricle remodeling, matrix metalloproteinases, multifactorial syndrome, oxidative stress, crucial structural, myocardium, ventricular dysfunction, pathophysiology, ventricular remodelling, therapeutic targets, enzyme inhibitors

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 12
ISSUE: 10
Year: 2012
Page: [1181 - 1191]
Pages: 11
DOI: 10.2174/1568026611208011181
Price: $58

Article Metrics

PDF: 15